GlassScriptPhysician profile
Zyad Kafri
NPI 1083747976
$1,638.97
in general payments reported to CMS, 2019-2025
24 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $99.95 · 2021: $19.58 · 2022: $188 · 2023: $272 · 2024: $183 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.53 |
| Education | $300.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $234.05 | 2025 | Verzenio, Jaypirca |
| Alexion Pharmaceuticals, INC. | $149.00 | 2019 | |
| Exelixis INC. | $134.86 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $121.74 | 2025 | |
| Beone Medicines USA, INC. | $121.04 | 2025 | Tevimbra |
| Abbvie INC. | $115.24 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2020 | |
| Beigene USA, INC. | $83.84 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $80.19 | 2019-2023 | Darzalex, Carvykti, Tecvayli |
| Sobi, INC | $65.40 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $60.99 | 2022 | |
| Genentech USA, INC. | $55.22 | 2023-2025 | Polivy, Columvi |
| Genzyme Corporation | $49.45 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $47.56 | 2019-2024 | Calquence |
| Novartis Pharmaceuticals Corporation | $36.78 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $33.47 | 2024 | Onivyde |
| Blueprint Medicines Corporation | $31.87 | 2023 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $21.76 | 2019 | |
| Celgene Corporation | $19.58 | 2021 | |
| Genmab U.S., INC. | $18.57 | 2024 | Epkinly |
| Terumo Bct, INC. | $17.56 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.64 | 2023 | |
| Astellas Pharma US INC | $14.29 | 2023 | Xospata |
| E.R. Squibb & Sons, L.L.C. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zyad Kafri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.